Liver disease in atrial fibrillation is associated with reduced oral anticoagulant prescription and higher risk of adverse outcomes, especially in patients not receiving anticoagulants.
Does liver disease impact OAC prescription and adverse outcomes in European and Asian patients with atrial fibrillation?
Liver disease in patients with atrial fibrillation is associated with reduced oral anticoagulant prescription and higher risk of adverse outcomes, regardless of European or Asian ethnicity.
Absolute Event Rate: 0% vs 0%
In AF, LD is associated with reduced OAC prescription, especially in Europe, and a higher risk of adverse outcomes, particularly in patients not receiving OAC, with no significant differences between European and Asian cohorts.
Mei et al. (Thu,) reported a other. Liver disease in atrial fibrillation is associated with reduced oral anticoagulant prescription and higher risk of adverse outcomes, especially in patients not receiving anticoagulants.